Wang Qian, Zeng Zhen, Nan Junjie, Zheng Yongqiang, Liu Huanbing
Department of General Practice, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Department of Geriatric Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Front Oncol. 2022 Mar 14;12:852347. doi: 10.3389/fonc.2022.852347. eCollection 2022.
Over the last decades, the number of patients diagnosed with thyroid carcinoma has been increasing, highlighting the importance of comprehensively evaluating causes of death among these patients. This study aimed to comprehensively characterize the risk of death and causes of death in patients with thyroid carcinoma.
A total of 183,641 patients diagnosed with an index thyroid tumor were identified from the Surveillance, Epidemiology, and End Result database (1975-2016). Standardized mortality rates (SMRs) for non-cancer deaths were calculated to evaluate mortality risk and to compare mortality risks with the cancer-free US population. Cumulative mortality rates were calculated to explore the factors associated with higher risk of deaths.
There were 22,386 deaths recorded during follow-up, of which only 31.0% were due to thyroid cancer and 46.4% due to non-cancer causes. Non-cancer mortality risk among patients with thyroid cancer was nearly 1.6-fold (SMR=1.59) that of the general population. Cardiovascular diseases were the leading cause of non-cancer deaths, accounting for 21.3% of all deaths in thyroid cancer patients. Non-cancer causes were the dominant cause of death in thyroid cancer survivors as of the third year post-diagnosis. We found that males with thyroid cancer had a higher risk of all-cause mortality compared with females. The risk of suicide was highest in the first post-diagnostic year (<1 year: SMR=1.51). The long-term risk of Alzheimer's disease was notably increased in thyroid cancer patients (>5 years: SMR=8.27).
Non-cancer comorbidities have become the major risks of death in patients with thyroid tumor in the US, as opposed to death from the tumor itself. Clinicians and researchers should be aware of these risk trends in order to conduct timely intervention strategies.
在过去几十年中,被诊断为甲状腺癌的患者数量一直在增加,这凸显了全面评估这些患者死亡原因的重要性。本研究旨在全面描述甲状腺癌患者的死亡风险和死亡原因。
从监测、流行病学和最终结果数据库(1975 - 2016年)中识别出总共183,641例被诊断患有原发性甲状腺肿瘤的患者。计算非癌症死亡的标准化死亡率(SMR),以评估死亡风险,并将死亡风险与无癌症的美国人群进行比较。计算累积死亡率,以探索与较高死亡风险相关的因素。
随访期间记录了22,386例死亡,其中仅31.0% 是由于甲状腺癌,46.4% 是由于非癌症原因。甲状腺癌患者的非癌症死亡风险几乎是普通人群的1.6倍(SMR = 1.59)。心血管疾病是非癌症死亡的主要原因,占甲状腺癌患者所有死亡的21.3%。非癌症原因是甲状腺癌幸存者自诊断后第三年起的主要死亡原因。我们发现,与女性相比,患有甲状腺癌的男性全因死亡风险更高。自杀风险在诊断后的第一年最高(<1年:SMR = 1.51)。甲状腺癌患者患阿尔茨海默病的长期风险显著增加(>5年:SMR = 8.27)。
在美国,非癌症合并症已成为甲状腺肿瘤患者的主要死亡风险,而非肿瘤本身导致的死亡。临床医生和研究人员应了解这些风险趋势,以便实施及时的干预策略。